Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Chayama, Kazuaki; Takahashi, Shoichi; Toyota, Joji; Karino, Yoshiyasu; Ikeda, Kenji; Ishikawa, Hiroki; Watanabe, Hideaki; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu

doi:10.1002/hep.24724

Public

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Published in Hepatology • Oct 10, 2011

Authors:

Kazuaki Chayama

Shoichi Takahashi

Joji Toyota

Abstract

UNLABELLED: Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg-IFN) and ribavirin (RBV) have limited therapeutic options. HCV genotype 1 is the most common worldwide and the most difficult to treat; genotype 1b is the most common subtype o...

Subject

Daclatasvir

Ribavirin

Discontinuation

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!